HDL: A molecular view of the "classic" antiatherogenic lipoprotein (original) (raw)

The Structure of Apolipoprotein A-I in High Density Lipoproteins

William Davidson

Journal of Biological Chemistry, 2007

View PDFchevron_right

Human Apolipoprotein A-II Enrichment Displaces Paraoxonase From HDL and Impairs Its Antioxidant Properties: A New Mechanism Linking HDL Protein Composition and Antiatherogenic Potential

Francisco Blanco-vaca, José Sánchez-quesada

Circulation Research, 2004

View PDFchevron_right

Apolipoprotein A-II, HDL metabolism and atherosclerosis

Jean-Charles Fruchart

Atherosclerosis, 2002

View PDFchevron_right

Pleiotropic Functions of HDL Lead to Protection from Atherosclerosis and Other Diseases

Panagiotis Fotakis

Dyslipidemia - From Prevention to Treatment, 2012

View PDFchevron_right

Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease

Jan Borén

Vascular health and risk management, 2007

View PDFchevron_right

Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk

Carlos Mendivil

JCI insight, 2018

View PDFchevron_right

A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family

Antonio Capurso

Journal of Clinical Investigation, 1980

View PDFchevron_right

Human HDL containing a novel apoC-I isoform induces smooth muscle cell apoptosis

Robert Brocia

Cardiovascular Research, 2013

View PDFchevron_right

HDL and arteriosclerosis: beyond reverse cholesterol transport

Arnold Von Eckardstein, Beate Kehrel

Atherosclerosis, 2002

View PDFchevron_right

Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL

Alaa Othman

Atherosclerosis, 2015

View PDFchevron_right

Functionality of High-Density Lipoprotein as Antiatherosclerotic Therapeutic Target

Theo Van Berkel

Arteriosclerosis, Thrombosis, and Vascular Biology, 2016

View PDFchevron_right

Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice

Bela Asztalos

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012

View PDFchevron_right

HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property

stephane LOYAU

The FASEB Journal, 2009

View PDFchevron_right

HDL in atherosclerosis: actor or bystander?

Bela Asztalos

Atherosclerosis Supplements, 2003

View PDFchevron_right

HDL, Atherosclerosis, and Emerging Therapies

Anouar Hafiane

Cholesterol, 2013

View PDFchevron_right

HDL and endothelial function: from molecular mechanisms to clinical observations

Alberico Catapano

Future Lipidology, 2006

View PDFchevron_right

HDL and endothelial protection

A. Levoye

British Journal of Pharmacology, 2013

View PDFchevron_right

Distribution of ApoA-I-Containing HDL Subpopulations in Patients With Coronary Heart Disease

Richard V Milani

2010

View PDFchevron_right

Significance of the hydrophobic residues 225-230 of apoA-I for the biogenesis of HDL

Panagiotis Fotakis, E. Stratikos, C. Gkolfinopoulou, Angeliki Chroni

The Journal of Lipid Research, 2013

View PDFchevron_right

HDL subpopulations containing apoA-I without apoA-II (LpA-I) in patients with angiographically proven coronary artery disease

Adrian Strzelecki

Journal of cardiology, 2016

View PDFchevron_right

Dysfunctional HDL and atherosclerotic cardiovascular disease

Robert Rosenson

Nature Reviews Cardiology, 2015

View PDFchevron_right

ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator

Shinji Yokoyama

Lipids in health and disease, 2017

View PDFchevron_right

Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL

Angeliki Chroni

Journal of Molecular Medicine, 2006

View PDFchevron_right

Apolipoproteins A-IV and A-V are acute-phase proteins in mouse HDL

Philippe Duchateau

Atherosclerosis, 2004

View PDFchevron_right

Physiochemically modified apolipoprotein B-containing lipoproteins and the risk of cardiovascular disease

Robert Rosenson

Journal of Internal Medicine, 2010

View PDFchevron_right

HDL: The ‘new’ target of cardiovascular medicine

Beatrice Dal Pino

International Journal of Cardiology, 2006

View PDFchevron_right

Structure/Function Relationships of Apolipoprotein A-I Mimetic Peptides: Implications for Antiatherogenic Activities of High-Density Lipoprotein

Amar Sethi

Circulation Research, 2010

View PDFchevron_right